|

neoadjuvant anti-PD-1 plus chemotherapy Clinical Trials

1 actively recruiting trial

Top Sponsors

  • Shanghai Zhongshan Hospital1

Indications

  • Esophageal Squamous Cell Carcinoma1
  • Neoadjuvant Chemoimmunotherapy1
  • Cancer1

Other1 trial

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.